| Recruiting | Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma NCT07340151 | The University of Texas Health Science Center at San Antonio | N/A |
| Recruiting | The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy NCT06282809 | HistoSonics, Inc. | N/A |
| Recruiting | Is the 3D-PANC MSP Model Superior to CT for Assessing Response to Neoadjuvant Treatment in PCA Patients? NCT06582342 | Fundación para la Investigación del Hospital Clínico de Valencia | — |
| Recruiting | Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Ad NCT05821556 | National Cancer Institute, Naples | Phase 2 |
| Suspended | Switch Maintenance in Pancreatic NCT05419479 | James Cleary, MD, PhD | Phase 1 / Phase 2 |
| Recruiting | Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperativ NCT05116072 | University Hospital, Lille | Phase 1 / Phase 2 |
| Unknown | Randomized Trial for Optimal Number of Passes Required for Molecular Profiling During EUS-FNB of Pancreatic Ca NCT05043532 | Orlando Health, Inc. | N/A |
| Recruiting | Neoadjuvant mFOLFIRINOX With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adenocarcinoma NCT04911816 | West Virginia University | Phase 1 / Phase 2 |
| Terminated | FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer NCT04141995 | University of Nebraska | Phase 2 |
| Recruiting | Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma NCT04543071 | Gulam Manji | Phase 2 |
| Completed | Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma NCT03871959 | Centre Leon Berard | Phase 1 |
| Withdrawn | Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B NCT03778879 | Alan Katz | Phase 1 / Phase 2 |
| Terminated | Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas NCT03490760 | Baptist Health South Florida | Phase 2 |
| Completed | Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma NCT03717298 | Catalysis SL | Phase 2 |
| Unknown | PEN-866 in Patients With Advanced Solid Malignancies NCT03221400 | Tarveda Therapeutics | Phase 1 / Phase 2 |
| Completed | First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine NCT02564146 | AIO-Studien-gGmbH | Phase 2 |
| Terminated | Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer ( NCT02707328 | The Cooper Health System | Phase 1 |
| Completed | A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer NCT02030860 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Completed | Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas NCT02037230 | University of Michigan Rogel Cancer Center | Phase 1 / Phase 2 |
| Completed | SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma NCT01357525 | David A. Clump, MD, PhD | N/A |
| Unknown | A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer NCT02707315 | The Cooper Health System | EARLY_Phase 1 |
| Terminated | Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas NCT01318642 | NantBioScience, Inc. | Phase 2 |
| Completed | Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastati NCT01497392 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy NCT01484860 | University Health Network, Toronto | Phase 2 |
| Withdrawn | Pancreatic Enzyme Suppletion in Pancreatic Cancer NCT01401387 | Foundation for Liver Research | Phase 4 |
| Completed | Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors NCT01447732 | Kyowa Kirin Co., Ltd. | Phase 1 |
| Completed | QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas NCT01231347 | NantCell, Inc. | Phase 3 |
| Terminated | PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer NCT01227018 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Completed | Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Ca NCT01222689 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors NCT01233505 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer NCT01232829 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer NCT01192763 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tum NCT01145456 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas NCT00948688 | Massachusetts General Hospital | Phase 1 / Phase 2 |
| Completed | Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer NCT00735917 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer NCT00577889 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Perioperative Therapy for Resectable Pancreatic Cancer NCT00609336 | University of Washington | Phase 2 |
| Terminated | Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have NCT00585845 | Anza Therapeutics, Inc. | Phase 1 |
| Completed | Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer NCT01068327 | University of Nebraska | Phase 1 |
| Completed | QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancrea NCT00630552 | NantCell, Inc. | Phase 1 / Phase 2 |
| Completed | Dasatinib in Treating Patients With Metastatic Pancreatic Cancer NCT00474812 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors NCT00462553 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer NCT00375310 | Indiana University School of Medicine | Phase 1 |
| Completed | Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer P NCT00383760 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer NCT00366457 | Massachusetts General Hospital | Phase 2 |
| Completed | Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer NCT00331682 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients NCT00114179 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Loca NCT00096070 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer NCT00095966 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pan NCT00091026 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Ca NCT00088894 | National Cancer Institute (NCI) | Phase 3 |
| Completed | CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer NCT00075647 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreat NCT00063947 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Ad NCT00047307 | National Cancer Institute (NCI) | Phase 1 |
| Completed | UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer NCT00039403 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer NCT00028834 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally A NCT00026104 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer NCT00028496 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the P NCT00020345 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Withdrawn | Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Panc NCT00253526 | National Cancer Institute (NCI) | Phase 2 |